Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AMRS

Amyris (AMRS) Stock Price, News & Analysis

About Amyris Stock (NASDAQ:AMRS)

Key Stats

Today's Range
N/A
50-Day Range
$0.05
$1.17
52-Week Range
N/A
Volume
46.75 million shs
Average Volume
12.59 million shs
Market Capitalization
$18.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Stock News Headlines

Amyris, Inc. (AMRS)
They laughed when he picked Nvidia in 2016…
Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right now
Amyris Receives Court Approval for Restructuring Plan
See More Headlines

AMRS Stock Analysis - Frequently Asked Questions

Amyris, Inc. (NASDAQ:AMRS) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. Amyris's revenue for the quarter was up 39.7% on a year-over-year basis.

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE) and AT&T (T).

Company Calendar

Last Earnings
11/08/2021
Today
10/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Specialty Chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
1,598
Year Founded
2003

Profitability

Net Income
$-528,510,000.00
Net Margins
-229.12%
Pretax Margin
-235.25%

Debt

Sales & Book Value

Annual Sales
$269.85 million
Book Value
($1.52) per share

Miscellaneous

Free Float
235,299,000
Market Cap
$18.47 million
Optionable
Optionable
Beta
1.19

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:AMRS) was last updated on 10/2/2024 by MarketBeat.com Staff
From Our Partners